AstraZeneca’s Imfinzi meets PFS primary endpoint in Phase III HCC trial

AstraZeneca has reported positive topline results from the EMERALD-1 Phase III clinical trial of Imfinzi (durvalumab) to treat hepatocellular carcinoma (HCC).

The trial investigated Imfinzi plus transarterial chemoembolisation (TACE) and Roche’s Avastin (bevacizumab) versus TACE alone in HCC patients who are eligible for embolisation, a procedure that blocks the blood supply to the tumour and can deliver chemotherapy or radiation therapy directly to the liver.